Our Shareholders

Melbourne is home to two outstanding universities, Monash University and the University of Melbourne, both ranked in the global top 35 in 2019 for Life Sciences and Medicine (2019 QS World University Rankings by Subject). Joining these two powerhouses to support the collaborative joint venture BioCurate, is the Victorian State Government, the nation’s largest investor in the life sciences.

The combined research strengths of Monash University and the University of Melbourne are world class, placing them in the top 5 globally in pharmacology, metabolism, and immunology, and in the top 10 in paediatrics, neurosciences and cardiology – thereby covering some of the most debilitating, costly diseases in the modern world.

The Universities collectively invest approximately AUD1B per annum in medical research funding and in 2016 attracted nearly half of the Australian national grant funding pool. Both Universities are members of the ‘Group of Eight’, an alliance of leading Australian universities recognised for their excellence in teaching as well as research. Between them, the Universities employ approximately 4,000 FTE staff in the biomedical sciences and provide major research infrastructure, healthcare and clinical research capabilities.

As individual institutions, Monash University and the University of Melbourne have differing, yet potentially highly complementary areas of expertise required for the early drug development process. This provides a compelling opportunity for BioCurate to be the catalyst to identify and leverage this combined expertise and build a strong pipeline of new drug targets with the potential to make a significant impact both medically and commercially.

 

Monash University is Australia’s largest and most international university. Its extensive educational offering, delivered across 10 faculties, includes undergraduate, postgraduate and research courses. Monash is a research-intensive university, known for some significant and lasting discoveries that have delivered impact beyond the academic community.

The University is home to a range of world-leading facilities and technologies, giving it wide-ranging capabilities across many fields, sectors and industries. Monash works with a variety of industry, government and community groups, allowing its researchers to share their discoveries with the world.

Monash is a truly global institution, with four Australian campuses, a campus in Malaysia, a joint graduate school in China, a learning centre in Italy, a research centre in India and over 100 international partners.

The 2019 QS World University Rankings by Subject placed Monash University third in the world for pharmacy and pharmacology, meaning that Monash University continues to be number one in that area in Australia and within the Asia-Pacific region. Monash University has averaged a top 10 ranking in the discipline since the subject rankings were introduced in 2011. In addition, Monash University ranks first in Australia for chemistry.

In the most recent round of the Excellence in Research (ERA) for Australia rankings, Monash University achieved world standard status across all disciplines and the highest possible score of five in 10 research disciplines, including Pharmacology and Pharmaceutical Sciences, Medicinal and Biomolecular Chemistry, and Nanotechnology. Faculty industry engagement teams help researchers to commercially develop their projects and are a vital link in the BioCurate value chain.

 

The University of Melbourne is the leading centre of higher education and research in Australia. Founded in 1853, it’s situated in the heart of one of the world’s most liveable cities.  With a strong research performance and excellence in learning and teaching, the University is consistently positioned with the world’s leading universities and is currently ranked number one in Australia and 32 in the world.

With a research expenditure second only to that of CSIRO in Australia, over 100 research centres and institutes, and more than 8,000 staff and 60,000 students it brings together expertise from across the University, and connects with thought leaders around the world to tackle society’s complex problems in innovative ways.   Researchers at the University of Melbourne are at the forefront of international discoveries in fields as diverse as human rights law, Indigenous linguistics, quantum technology and medical genomics.  The University fosters a culture of discovery in collaboration with industry and research partners, bringing together inquiring minds, exciting ideas and diverse disciplines to address the big questions of our time.  Consistent with our commitment to embrace Indigenous knowledges, we look to recruit and nurture Indigenous researchers to build a stronger research cohort both within and beyond the University.

Cutting edge in design, the specialised precincts of the University of Melbourne are dedicated, dynamic spaces built around human expertise in health, the arts, innovation and engineering. From the world leading Biomedical Precinct to the revitalised Melbourne Arts Precinct, the University is helping shape the future of the city.  Through co-location and exploration, these innovative spaces are fostering debate, challenging traditional norms, and harnessing the distinctive talents of our students, researchers and partners as they come together to create and shape a changing world.

Embedded within each faculty, members of the Research, Innovation and Commercialisation team provide UoM staff with commercial advice and support in the pursuit of their strategic plans and are a vital conduit between BioCurate and the researchers.

 

Victoria is one of the world’s leading life science hubs, including the medical technology, biotechnology and pharmaceutical industry segments, which is supported by 16 major medical research institutes, 11 teaching hospitals and 9 universities.

Victoria is a leading generator of new ideas contributing to drug discovery and development, and to the global pipeline of new drugs. Built on world-class research, a vibrant biotech sector, key R&D infrastructure and manufacturing expertise, Victoria is currently home to 48 ASX-listed pharmaceutical and biotechnology companies, with a combined market capitalisation of around $100 billion. More than 22 pharmaceutical manufacturers are based in Melbourne producing a variety of products for international markets using advanced manufacturing technologies. In 2017, Victoria’s pharmaceutical products exports accounted for $1.56 billion, an increase of 72% since 2015. Pharmaceuticals are now Victoria’s highest-value manufactured export product.

This pre-eminent position has been made possible by the consistent and long-term support of the Victorian Government for the sector, providing significant funding for capabilities and supporting infrastructure.

Return to About
Share